Search
Find a recruiting study
7,120 recruiting studies with US sites, from the official ClinicalTrials.gov registry (refreshed Oct 26, 2026). No sign-up needed.
Most recently updated studies · page 52 of 297
- RecruitingPhase 3
A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.
- Location
- Redlands, CA + 10 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)
Ionis Pharmaceuticals, Inc.
- Location
- Carrboro, NC
- Eligibility basics
- Ages 2–50
- RecruitingPhase 3
A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.
- Location
- Jacksonville, FL + 1 other US site
- Eligibility basics
- Ages 18+
- Recruiting
Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes
Medtronic MiniMed, Inc.
- Location
- Chula Vista, CA + 9 other US sites
- Eligibility basics
- Ages 2–80
- Recruiting
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
Kuros Biosurgery AG
- Location
- Hartford, CT + 8 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
Basilea Pharmaceutica
- Location
- Birmingham, AL + 21 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
Valencia Technologies Corporation
- Location
- Homewood, AL + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease
Calico Life Sciences LLC
- Location
- Boston, MA + 2 other US sites
- Eligibility basics
- Ages 6 mo+
- Recruiting
Atrial Flutter Ablation in the iCMR
Imricor Medical Systems
- Location
- Baltimore, MD + 2 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Birmingham, AL + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie
- Location
- Fountain Valley, CA + 29 other US sites
- Eligibility basics
- Ages 12–63
- RecruitingPhase 2/Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Scottsdale, AZ + 34 other US sites
- Eligibility basics
- Ages 55–95
- RecruitingPhase 2
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Azure Biotech Inc.
- Location
- Saint Paul, MN
- Eligibility basics
- Ages 45–60 · Women only
- Recruiting
The HEARTFELT Study
Heartfelt Technologies
- Location
- Hackensack, NJ + 1 other US site
- Eligibility basics
- Ages 22+
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
- Location
- Homewood, AL + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Cabaletta Bio
- Location
- Orange, CA + 16 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Sanofi
- Location
- Birmingham, AL + 16 other US sites
- Eligibility basics
- Ages 16–75
- RecruitingPhase 1/Phase 2
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
Arbor Biotechnologies
- Location
- Rochester, MN
- Eligibility basics
- Ages 6–64
- Recruiting
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
Apreo Health, Inc.
- Location
- Birmingham, AL + 17 other US sites
- Eligibility basics
- Ages 40–84
- RecruitingPhase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
AstraZeneca
- Location
- Anniston, AL + 2 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Lumos Pharma
- Location
- Birmingham, AL + 30 other US sites
- Eligibility basics
- Ages 3–11
- RecruitingPhase 2/Phase 3
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
Kiniksa Pharmaceuticals International, plc
- Location
- Gilbert, AZ + 29 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Annexon, Inc.
- Location
- Phoenix, AZ + 19 other US sites
- Eligibility basics
- Ages 8–85
- Recruiting
Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area
Boston Scientific Corporation
- Location
- New York, NY + 3 other US sites
- Eligibility basics
- Ages 18+
Data source: deploy-time snapshot of the ClinicalTrials.gov API. How we list studies